BREDIS Healthcare Selected for '2024 Materials & Components Technology Development Program' by the Ministry of Trade, Industry and Energy (MOTIE)

BREDIS Healthcare announced on the 14th that it has been officially selected for the 2024 Materials & Components Technology Development Program run by the Ministry of Trade, Industry and Energy (MOTIE). The program aims to develop ultrasensitive 3D nano-optical enhancement materials for cancer diagnostic devices, with total government funding of KRW 13.5 billion over five years. The project is organized into an overall coordination task and three sub-tasks, with BREDIS Healthcare leading Sub-task 2. The goal of Sub-task 2 is to develop a highly sensitive biochip for multiplex genetic and immunoassay diagnostics — an advanced biochip capable of simultaneously detecting cancer-related genetic mutations and protein biomarkers — and to conduct clinical trials based on the resulting technology. Chung-Ang University (Professor Jaebum Joo), the Korea Research Institute of Bioscience and Biotechnology (Dr. Taejoon Kang), and the Ulsan National Institute of Science and Technology (Professor Joohun Kang) are participating as joint research institutions, contributing their expertise in ultrasensitive biochip development and sample pretreatment technology. "Our goal is to improve the accuracy and efficiency of early cancer diagnosis by developing a plasmonic-based biochip for multiplex immunoassays and genetic mutation detection," said Professor Jaebum Joo of Chung-Ang University. "By converging advanced bio-technology with digital healthcare, BREDIS Healthcare aims to present a new paradigm for diagnosis and treatment and help build a healthier future for humanity," said Hyundoo Hwang, CEO of BREDIS Healthcare. "We are committed to using innovative technology to create a world where anyone can easily maintain their health."